Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naïve Participants

NCT05222607 is registered in ClinicalTrials.gov with Merz North America, Inc. as lead sponsor.

NCT NCT05222607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05222607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naïve Participants
Lead sponsor
Merz North America, Inc.
Phase
Observational
Overall status
Terminated
Start date
February 10, 2023
Completion date
May 18, 2023
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines and canthal lines and/or horizontal forehead lines in the upper face